US-based C4 Therapeutics Inc., (NASDAQ: CCCC) has announced receiving clinical trial approval from the US FDA for its pipeline candidate, CFT8919. This orally bioavailable BiDAC degrader is designed to target EGFR L858R mutations and has demonstrated good activity and selectivity against solid tumors carrying these mutations.
Pre-Clinical Success and Potential Impact on NSCLC
Pre-clinical studies have shown that CFT8919 exhibits activity in both in vivo and in vitro models of EGFR L858R-driven non-small cell lung cancer (NSCLC). The drug targets a broad range of drug-resistant mutations and has intracranial activity, which could potentially prevent or treat brain metastasis in patients with these tumors.
Betta Pharmaceuticals Secures Exclusive Licensing Agreement for Greater China
In May of this year, China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) entered into an exclusive licensing agreement with C4 Therapeutics. Through this agreement, Betta Pharmaceuticals obtained exclusive development and commercialization rights to CFT8919 in Greater China, including Hong Kong SAR, Macau SAR, and Taiwan. This partnership highlights the global interest in CFT8919 and its potential role in addressing unmet medical needs in the treatment of EGFR L858R-mutated cancers.-Fineline Info & Tech
